

30 copy

Independent Auditor's Report on the audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors of
JC Biotech Private Limited

Report on the audit of Financial Results

Opinion

We have audited the accompanying statement of audited financial results of **JC Biotech Private Limited** (the "Company"), for the year ended 31st March, 2023 (the "Statement"), attached herewith, being submitted by the Company in connection with the consolidation of the Company's financial information with **Advanced Enzymes Technologies Limited** (the "Holding Company"), pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India of the total comprehensive income (comprising of net loss and other comprehensive loss) and other financial information of the Company for the year ended 31st March, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Financial Results

These financial results have been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation of the Statement that gives a true and fair view of the net and other comprehensive income of the Company and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS -34), 'Interim Financial Reporting' prescribed under

Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on the operating effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report.



However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Restriction of Use

This report is issued at the request of the Company and is intended solely for the information and use of the Holding Company for the purpose of presentation of its audited consolidated financial results for year ended 31st March, 2023 and is not intended to be and should not be used for any other purpose.

For NAC And Associates LLP.

ICAI Firm Registration Number: 119375W/S200011

Chartered Accountants

Nikhil Surana

Partner

Membership No.: 232997

UDIN: 23232997BGUHAN5565



Place: Secunderabad

Date : 01.05.2023

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF J C BIOTECH PRIVATE LIMITED

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of J C Biotech Private Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2023, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended on that date, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, the loss and other comprehensive loss, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements


Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.


We communicate with those charged with governance regarding, among other matters, the planned



- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of Section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of Section 197 of the Act.

- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
- i) The Company has disclosed the impact of pending litigations on its financial position in its financial statements - Refer Note 59 to the financial statements.
- ii) The Company did not have any long-term contracts including derivative contracts for which there were material foreseeable losses.
- iii) There were no amounts required to be transferred to the Investor Education and Protection Fund by the Company.
- iv) (a) The management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (b) The management has represented, that, to the best of its knowledge and belief, no funds have been received by the company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (c) Based on audit procedures that have considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material mis-statement.




ANNEXURE A REFERRED TO IN PARAGRAPH 1 UNDER THE HEADING "REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS" OF OUR REPORT OF EVEN DATE TO THE MEMBERS OF M/s. J C BIOTECH PRIVATE LIMITED

On the basis of our examination of the books and records of the Company carried out in accordance with the auditing standards generally accepted in India and according to the information and explanations given to us, we state that:

- i) a) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment ('Fixed Assets').
- b) All the Property, Plant and Equipment have been physically verified by the management at reasonable intervals during the year, which in our opinion is reasonable having regard to the size of the Company and nature of its fixed assets. No material discrepancies were noticed on such verification.
- c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties are held in the name of the Company.
- d) The Company has not carried out revaluation of its Property, Plant and Equipment and accordingly, reporting requirements of paragraph 3(i)(d) of the Order are not applicable to the Company.
- e) No proceedings have been initiated or are pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.
- ii) a) According to the information and explanation given to us, the management has conducted physical verification of inventory at reasonable intervals during the year and the coverage and procedure for such verification is appropriate. Inventory in-transit have been verified by the management with reference to the subsequent receipt of goods. The discrepancies noticed on verification between the physical stock and book records were not material in relation to the operations of the Company and have been properly dealt with in the books of account.
- b) The Company has been sanctioned working capital limits of Rs. 5.00 crores, in aggregate, during the year, from a bank on the basis of security of its current assets. In our opinion and based on the information and explanations given to us and our verification of the stock statements submitted by the Company to the bank in relation to the aforesaid working capital limits, such stock statements are, broadly in all material respects, in agreement with the books of account of the Company except for the deviations detailed in Note 43 of the audited financial statements.



- viii) According to the records maintained by the Company and information and explanations given to us, there were no transactions relating previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.
- ix) a) According to the records maintained by the Company and information and explanations given to us, the Company has not defaulted in repayment of loans to banks and financial institutions. The Company does not have any loans from Government or dues to debenture holders.
- b) According to the information and explanations given to us and on the basis of our audit procedures, we report that the Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- c) The Company has not taken any term loans during the year and there are no outstanding term loans at the beginning of the year and accordingly, reporting under clause 3(ix)(c) of the Order is not applicable.
- d) According to the information and explanations given to us, and the procedures performed by us, and on an overall examination of the financial statements and financial ratios of the Company, we report that no funds raised on short-term basis have been used for long-term purposes.
- e) The Company does not have any subsidiaries, associates and joint ventures and accordingly, reporting requirements of paragraph 3(ix)(e) of the Order are not applicable to the Company.
- f) The Company does not have any subsidiaries, associates and joint ventures and accordingly, reporting requirements of paragraph 3(ix)(f) of the Order are not applicable to the Company.
- x) In our opinion and according to the information and explanations given to us, the Company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the year and accordingly, reporting requirements of paragraph 3(x) of the Order are not applicable to the Company.
- xi) a) During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing standards in India and according to the information and explanations given to us, we have neither come across any instance of fraud by the Company or on the Company by its officers or employees, noticed or reported during the year, nor have we been informed of such case by the management.
- b) No report under sub-section (12) of Section 143 of the Act has been filed in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.
- c) No whistle blower complaints have been received during the year by the Company.



compliance of with provisions of Sub Section (6) of Section 135 of the said Act. This matter has been disclosed in Note 52 to the Financial Statements.

For N A C And Associates LLP
ICAI FRN: 119375W/S200011
Chartered Accountants



Nikhil

Nikhil Surana

Partner

Membership No.: 232997

UDIN: 23232997BGUHAO7688

Place: Secunderabad

Date : 01.05.2023

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

A company's internal financial control over financial reporting includes those policies and procedures that

- 1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- 2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the company;
- 3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements;
- 4) also provide reasonable assurance by the internal auditors through their internal audit reports given to the organisation from time to time.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, broadly in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India".

For N A C And Associates LLP
ICAI FRN: 119375W/S200011
Chartered Accountants



Nikhil Surana
Nikhil Surana
Partner
Membership No.: 232997
UDIN: 23232997BGUHAO7688

Place: Secunderabad

Date : 01.05.2023

50 COPY


J C BIOTECH PRIVATE LIMITED
CIN NO. : U65993TG1991PTC013624
Balance Sheet as at 31st Mar, 2023

(Amount in INR thousands, unless otherwise stated)

	Notes	As at 31-Mar-23	As at 31-Mar-22
ASSETS			
Non-current assets			
Property, Plant and Equipment	5	5,12,213	4,25,962
Capital work-in-progress	6A	14,729	56,501
Other intangible assets	6	133	82
Financial assets			
Other financial assets	7	13,844	10,752
Other non-current assets	8	1,259	6,184
Total non-current assets		5,42,177	4,99,481
Current assets			
Inventories	9	1,01,758	1,21,416
Financial assets			
Trade receivables	10	45,670	68,899
Cash and cash equivalents	11	249	425
Other financial assets	12	12,035	12,043
Current tax assets (net)	13	7,439	1,326
Other current assets	14	30,888	7,821
Total current assets		1,98,039	2,11,931
Total assets		7,40,217	7,11,412
EQUITY AND LIABILITIES			
Equity			
Equity share capital	15	2,07,112	2,07,112
Other equity	16	3,93,910	4,13,362
Total equity		6,01,022	6,20,474

The accompanying notes are an integral part of the financial statements.

As per our report of even date
For NAC And Associates LLP
Chartered Accountants
Firm Registration No.
119375W/S200011


Nikhil Surana
Partner
Membership No: 232997/ICAI

Place: Hyderabad
Date: 01-05-2023

For and on behalf of the Board of
J C Biotech Private Limited

Naveen ki Bondalapati
B.Naveen Krishna
Executive Director
DIN: 07137132

U. U. Kabra
Mukund Madhusudan Kabra
Director
DIN: 00148294



Pranit
TSSN Sivarama Prasad
Chief Finance Officer

Pranit Chandrakant Dalvi
Company Secretary
Membership No: A62392

Liabilities**Non-current liabilities**

Financial liabilities

Provisions	17	32	562
Deferred Tax Liabilities (Net)	18	39,225	48,597
Total non-current liabilities		<u>39,257</u>	<u>49,159</u>

Current liabilities

Financial liabilities

Borrowings	19	49,821	17,641
Trade payables	20		
i)total outstanding dues of micro enterprises and small enterprises		1,964	1,480
ii)total outstanding dues of creditors other than micro enterprise and small enterprise		30,009	6,570
Other financial liabilities	21	12,508	9,433
Other current liabilities	22	3,302	5,893
Provisions	17	2,334	763

Total current liabilities		<u>99,938</u>	<u>41,780</u>
----------------------------------	--	---------------	---------------

Total liabilities		<u>1,39,195</u>	<u>90,938</u>
--------------------------	--	-----------------	---------------

Total equity and liabilities		<u>7,40,217</u>	<u>7,11,412</u>
-------------------------------------	--	-----------------	-----------------

See accompanying notes to the financial statements 1-61

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For NAC And Associates LLP

Chartered Accountants

Firm Registration No.

119375W/S200011


Nikhil Surana

Partner

Membership No: 232997/ICAI

Place: Hyderabad

Date: 01-05-2023

For and on behalf of the Board of

J C Biotech Private Limited


B. Naveen Krishna

Executive Director

DIN: 07137132


Mukund Madhusudan Kabra

Director

DIN:00148294





TSSN Sivarama Prasad
Chief Finance Officer

Pranit Chandrakant Dalvi
Company Secretary
Membership No: A62392

J C BIOTECH PRIVATE LIMITED

Statement of Profit and Loss for the year ended 31st Mar, 2023
(Amount in INR thousands, unless otherwise stated)

		Year ended Year ended	
	Notes	31-Mar-23	31-Mar-22
Income			
Revenue from operations	23	5,01,780	5,03,579
Other income	24	679	543
Total income		5,02,459	5,04,123
Expenses			
Cost of material consumed	25	1,49,503	1,54,615
Changes in inventories of finished goods and work-in-progress	26	37,660	(37,688)
Employee benefits expense	27	71,852	64,765
Finance costs	28	4,175	3,158
Depreciation and amortization expense	29	38,104	36,101
Other expenses	30	2,28,549	1,80,232
Total expenses		5,29,844	4,01,182
Profit /(Loss) before exceptional items and tax		(27,385)	1,02,940
Tax expense			
Current tax	31	-	29,564
Deferred tax	31	(6,941)	1,024
Tax Adjustment For Earlier Years		(2,027)	(95)
Total income tax expense		(8,969)	30,493

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For NAC And Associates LLP

Chartered Accountants

Firm Registration No.

119375W/S200011

Nikhil
Nikhil Surana

Partner

Membership No: 232997/ICAI

Place: Hyderabad

Date: 01-05-2023

For and on behalf of the Board of

J C Biotech Private Limited

Naveen K. Bondalapati

B.Naveen Krishna

Executive Director

DIN: 07137132

Mukund Madhusudan Kabra

Mukund Madhusudan Kabra

Director

DIN: 00148294

TSSN Sivarama Prasad

TSSN Sivarama Prasad

Chief Finance Officer

Pranit Chandrakant Dalvi

Pranit Chandrakant Dalvi

Company Secretary

Membership No: A62392



Profit/(Loss) for the year from continuing operations		(18,416)	72,447
Profit for the period		<u>(18,416)</u>	<u>72,447</u>
Other comprehensive income			
<i>Items that will not be reclassified to profit or loss</i>			
Remeasurement of net employees defined benefit liability		(1,435)	(928)
Income tax effect on these items		399	258
		<u>(1,036)</u>	<u>(670)</u>
Other comprehensive income for the year, net of tax		<u>(1,036)</u>	<u>(670)</u>
Total comprehensive income for the year		<u>(19,452)</u>	<u>71,777</u>
Earnings / (Loss) per share			
Basic earnings / (loss) per share (INR)	32	-0.89	3.50
Diluted earnings / (loss) per share (INR)	32	-0.89	3.50

See accompanying notes to the financial statements 1-61

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For NAC And Associates LLP

Chartered Accountants

Firm Registration No.

119375W/S200011

Nikhil

Nikhil Surana

Partner

Membership No: 232997/ICAI

Place: Hyderabad

Date: 01-05-2023



For and on behalf of the Board of

J C Biotech Private Limited

Naveen K. Bondalapati

B.Naveen Krishna

Executive Director

DIN: 07137132

M. M. Kabra

Mukund Madhusudan Kabra

Director

DIN: 00148294



Pranit

Pranit Chandrakant Dalvi

Company Secretary

Membership No: A62392

TSSN Sivarama Prasad

Chief Finance Officer